KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD.
The KDOQI work group reviewed the 2024 KDIGO CKD guideline and largely concurred with its recommendations, while providing a US-focused perspective on implementing newer therapies and team-based care.
Background
The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the 2024 KDIGO Clinical Practice Guideline for the Evaluation and Management of chronic kidney disease (CKD) and to interpret its statements and practice points for clinical practice in the United States. The KDIGO update was the first major revision since 2012 and reflects a substantially expanded evidence base.
Key recommendations
The work group generally concurred with KDIGO recommendations and practice points on CKD evaluation, risk assessment, and management options to slow CKD progression, address CKD-related complications, and improve cardiovascular outcomes. It acknowledged the growing evidence supporting newer agents, including sodium-glucose cotransporter 2 inhibitors for several CKD etiologies, and glucagon-like peptide 1 receptor agonists and nonsteroidal mineralocorticoid receptor antagonists for CKD in the setting of type 2 diabetes, and emphasized the importance of team-based care.
Clinical implications
The commentary discusses barriers and opportunities for implementing the 2024 KDIGO recommendations within US practice while the field continues to focus on earlier CKD identification and newer therapies. It is intended to help US clinicians apply the guideline within their own practice context rather than to replace the underlying KDIGO recommendations.
Category
KDIGO
Source
Am J Kidney Dis
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.